CY1122188T1 - Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιας - Google Patents
Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιαςInfo
- Publication number
- CY1122188T1 CY1122188T1 CY20191100972T CY191100972T CY1122188T1 CY 1122188 T1 CY1122188 T1 CY 1122188T1 CY 20191100972 T CY20191100972 T CY 20191100972T CY 191100972 T CY191100972 T CY 191100972T CY 1122188 T1 CY1122188 T1 CY 1122188T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fibrodysplasia
- progressive
- acvr2a
- acvr1
- acvr2b
- Prior art date
Links
- 230000000750 progressive effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102100034111 Activin receptor type-1 Human genes 0.000 abstract 4
- 101710105225 Activin receptor type-1 Proteins 0.000 abstract 4
- 102100021886 Activin receptor type-2A Human genes 0.000 abstract 4
- 101710191686 Activin receptor type-2A Proteins 0.000 abstract 4
- 102100027647 Activin receptor type-2B Human genes 0.000 abstract 4
- 101710191689 Activin receptor type-2B Proteins 0.000 abstract 4
- 239000005557 antagonist Substances 0.000 abstract 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 108010023082 activin A Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Abstract
Παρέχονται μέθοδοι για τη θεραπευτική αντιμετώπιση της Προοδευτικής Οστεοποιούς Ινοδυσπλασίας (FOP). Οι εν λόγω μέθοδοι περιλαμβάνουν τη χορήγηση σε ένα υποκείμενο που πάσχει από FOP ενός αποτελεσματικού σχήματος ενός ανταγωνιστή του υποδοχέα ακτιβίνης τύπου 2Α (ACVR2A) ή/και του υποδοχέα ακτιβίνης τύπου 2Β (ACVR2B) ή ενός ανταγωνιστή του υποδοχέα ακτιβίνης τύπου 1 (ACVR1). Οι ανταγωνιστές συμπεριλαμβάνουν πρωτεΐνες σύντηξης ενός ή περισσότερων εξωκυττάριων τομέων (ECD) των ACVR2A, ACVR2B ή/και ACVR1 και του τομέα Fc μιας βαριάς αλυσίδας της ανοσοσφαιρίνης, καθώς και αντισώματα κατά των ACVR2A, ACVR2B, ACVR1 ή της Ακτιβίνης Α.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049869P | 2014-09-12 | 2014-09-12 | |
US201562141775P | 2015-04-01 | 2015-04-01 | |
PCT/US2015/000100 WO2016039796A2 (en) | 2014-09-12 | 2015-09-14 | Treatment of fibrodysplasia ossificans progressiva |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122188T1 true CY1122188T1 (el) | 2020-11-25 |
Family
ID=54207748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100972T CY1122188T1 (el) | 2014-09-12 | 2019-09-17 | Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιας |
Country Status (28)
Country | Link |
---|---|
US (3) | US20160075772A1 (el) |
EP (2) | EP3191512B1 (el) |
JP (1) | JP6560341B2 (el) |
KR (1) | KR102564079B1 (el) |
CN (1) | CN107106648B (el) |
AU (1) | AU2015315829B2 (el) |
CA (1) | CA2960950C (el) |
CL (2) | CL2017000603A1 (el) |
CY (1) | CY1122188T1 (el) |
DK (1) | DK3191512T3 (el) |
ES (1) | ES2739605T3 (el) |
HR (1) | HRP20191929T1 (el) |
HU (1) | HUE046558T2 (el) |
IL (1) | IL251063B (el) |
LT (1) | LT3191512T (el) |
MA (1) | MA40621B1 (el) |
ME (1) | ME03541B (el) |
MX (1) | MX2017003175A (el) |
MY (1) | MY179654A (el) |
NZ (1) | NZ730773A (el) |
PL (1) | PL3191512T3 (el) |
PT (1) | PT3191512T (el) |
RS (1) | RS59412B1 (el) |
SG (2) | SG10201902175RA (el) |
SI (1) | SI3191512T1 (el) |
TW (1) | TWI688402B (el) |
WO (1) | WO2016039796A2 (el) |
ZA (1) | ZA201702112B (el) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX350355B (es) | 2011-11-14 | 2017-09-04 | Regeneron Pharma | Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a. |
TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
KR20180006386A (ko) | 2015-04-22 | 2018-01-17 | 얼라이브젠 유에스에이 인코포레이티드 | 신규한 근육 소모 질환 치료용 하이브리드 actriib 리간드 트랩 단백질 |
EP3415527A1 (de) * | 2017-06-14 | 2018-12-19 | Technische Universität Dresden | Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen |
JP2021515003A (ja) | 2018-03-01 | 2021-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 体組成を変更するための方法 |
CA3093205A1 (en) * | 2018-03-05 | 2019-09-12 | Saitama Medical University | Pharmaceutical composition for treating or preventing heterotopic ossification |
AU2019284762A1 (en) * | 2018-06-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | A rodent model of fibrodysplasia ossificans progressiva |
EP3806885A2 (en) | 2018-06-13 | 2021-04-21 | Kymab Limited | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone |
SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
WO2020028831A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva |
WO2020086730A1 (en) * | 2018-10-23 | 2020-04-30 | Keros Therapeutics, Inc. | Alk2 antibodies and methods of use thereof |
KR20210104744A (ko) * | 2018-12-18 | 2021-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법 |
KR20220139886A (ko) * | 2020-01-08 | 2022-10-17 | 리제너론 파아마슈티컬스, 인크. | 진행성 골화성 섬유이형성증의 치료 |
WO2021142260A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of acvr1 |
US20210393779A1 (en) * | 2020-06-18 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Activin a antibody formulations and methods of use thereof |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
IL310810A (en) * | 2021-09-03 | 2024-04-01 | Laekna Therapeutics Shanghai Co Ltd | Anti-ACVR2A antibodies and uses thereof |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
DE60045319D1 (de) | 1999-02-05 | 2011-01-13 | Samsung Electronics Co Ltd | Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
DE602005027309D1 (de) | 2004-01-16 | 2011-05-19 | Regeneron Pharma | Zur aktivierung von rezeptoren fähige fusionspolypeptide |
CA2891010C (en) | 2004-07-23 | 2022-09-20 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
US8859752B2 (en) * | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
KR20090088852A (ko) * | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법 |
CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
TW201907946A (zh) * | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
JP5270913B2 (ja) | 2007-12-26 | 2013-08-21 | サンゴバン・ティーエム株式会社 | 高電気抵抗高ジルコニア鋳造耐火物 |
CA2718403A1 (en) * | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
WO2009137075A1 (en) | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
WO2011158924A1 (ja) * | 2010-06-18 | 2011-12-22 | 独立行政法人国立精神・神経医療研究センター | 優性アレル発現抑制剤 |
WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
MX350355B (es) * | 2011-11-14 | 2017-09-04 | Regeneron Pharma | Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a. |
WO2014051109A1 (ja) | 2012-09-28 | 2014-04-03 | 協和発酵キリン株式会社 | 抗ヒトbmp9抗体および該抗体を有効成分とする異所性骨化疾患の治療剤 |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
US10260068B2 (en) | 2014-03-31 | 2019-04-16 | Sumitomo Dainippon Pharma Co., Ltd. | Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva |
US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
IL292578A (en) * | 2015-02-13 | 2022-06-01 | Sorrento Therapeutics Inc | Treatment using antibodies that bind to ctla4 |
AU2016255768B2 (en) | 2015-04-29 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
-
2015
- 2015-09-10 US US14/850,844 patent/US20160075772A1/en not_active Abandoned
- 2015-09-11 TW TW104130079A patent/TWI688402B/zh active
- 2015-09-14 CN CN201580049029.1A patent/CN107106648B/zh active Active
- 2015-09-14 LT LTEP15775835.0T patent/LT3191512T/lt unknown
- 2015-09-14 ME MEP-2019-279A patent/ME03541B/me unknown
- 2015-09-14 PL PL15775835T patent/PL3191512T3/pl unknown
- 2015-09-14 PT PT15775835T patent/PT3191512T/pt unknown
- 2015-09-14 MA MA40621A patent/MA40621B1/fr unknown
- 2015-09-14 NZ NZ730773A patent/NZ730773A/en unknown
- 2015-09-14 SG SG10201902175RA patent/SG10201902175RA/en unknown
- 2015-09-14 DK DK15775835.0T patent/DK3191512T3/da active
- 2015-09-14 SG SG11201701913SA patent/SG11201701913SA/en unknown
- 2015-09-14 KR KR1020177009673A patent/KR102564079B1/ko active IP Right Grant
- 2015-09-14 MY MYPI2017700819A patent/MY179654A/en unknown
- 2015-09-14 MX MX2017003175A patent/MX2017003175A/es unknown
- 2015-09-14 EP EP15775835.0A patent/EP3191512B1/en active Active
- 2015-09-14 ES ES15775835T patent/ES2739605T3/es active Active
- 2015-09-14 SI SI201530852T patent/SI3191512T1/sl unknown
- 2015-09-14 HU HUE15775835A patent/HUE046558T2/hu unknown
- 2015-09-14 IL IL251063A patent/IL251063B/en unknown
- 2015-09-14 CA CA2960950A patent/CA2960950C/en active Active
- 2015-09-14 EP EP19177741.6A patent/EP3604335A1/en not_active Withdrawn
- 2015-09-14 WO PCT/US2015/000100 patent/WO2016039796A2/en active Application Filing
- 2015-09-14 RS RSP20191331 patent/RS59412B1/sr unknown
- 2015-09-14 AU AU2015315829A patent/AU2015315829B2/en active Active
- 2015-09-14 JP JP2017513774A patent/JP6560341B2/ja active Active
-
2017
- 2017-03-10 CL CL2017000603A patent/CL2017000603A1/es unknown
- 2017-03-27 ZA ZA2017/02112A patent/ZA201702112B/en unknown
- 2017-08-28 US US15/688,740 patent/US20180111983A1/en not_active Abandoned
-
2018
- 2018-10-17 CL CL2018002962A patent/CL2018002962A1/es unknown
-
2019
- 2019-09-17 CY CY20191100972T patent/CY1122188T1/el unknown
- 2019-09-23 US US16/579,126 patent/US11407822B2/en active Active
- 2019-10-23 HR HRP20191929TT patent/HRP20191929T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122188T1 (el) | Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιας | |
CY1124428T1 (el) | Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1 | |
CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
CY1120281T1 (el) | Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail | |
CY1122528T1 (el) | Χιμαιρικοι υποδοχεις αντιγονου bcma | |
CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
CY1124787T1 (el) | Αντισωματα anti-gitr και μεθοδοι χρησης αυτων | |
CY1125008T1 (el) | Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων | |
CY1123925T1 (el) | Μια νεα μορφη il33, μεταλλαγμενες μορφες της il33, αντισωματα, δοκιμασιες και μεθοδοι χρησης των ιδιων | |
CO2018001405A2 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
CR20180225A (es) | Anticuerpo anti-tigit y métodos de uso | |
CY1124153T1 (el) | Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 | |
EA202190903A2 (ru) | Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний | |
PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
AR093788A1 (es) | Inmunoterapia con agentes de enlace | |
DOP2016000283A (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
MX2017007491A (es) | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
EA201790475A1 (ru) | Способы лечения системной красной волчанки с использованием доменного антитела против cd28 | |
TR201903312T4 (tr) | Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. | |
EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
EA201790314A1 (ru) | Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d |